As the new year sparks a wave of weight loss resolutions and millions turn to weight loss medications, rising costs and the ...

21 (UPI) --Zepbound, the new GLP-1 weight-loss ... "Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Dr. Sally Seymour of the FDA's ...

called the FDA’s approval a "promising advancement for the millions of people who suffer from this condition." "Zepbound promotes weight loss and has been shown to reduce apnea events." ...

The approval supports evidence that GLP-1 drugs improve overall health along with weight loss. In March, the FDA approved Wegovy, from Novo Nordisk, to reduce heart disease risk. Other studies are ...

The Food and Drug Administration has approved ... Health and Lilly USA. "Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss ...

The move comes as weight-loss ... when the FDA approved Wegovy for cardiovascular disease risk reduction early in 2024,” Juliette Cubanski, a deputy director of KFF, a nonpartisan health-care ...

The U.S. Food and Drug Administration (FDA ... improving overall health. The approval of Zepbound underscores the evolving landscape of OSA management, combining weight-loss benefits with improved ...

If untreated, obstructive sleep apnea raises the risk for a range of health issues ... Even before the FDA approval, some doctors have been prescribing weight-loss drugs to people with sleep ...

which was approved for weight loss for those with obesity, or who are overweight and have a weight-related health condition, in November 2023. Although the new FDA green light doesn’t expand the ...